Sagimet Biosciences Inc.SGMT
Health Care · Pharmaceuticals, Biotechnology & Life Sciences · NASDAQ · United States · sagimet.com
Sagimet Biosciences is a Foster City, CA clinical-stage biopharmaceutical company developing FASN inhibitors, led by denifanstat in Phase 3 for moderate-to-severe acne (AURORA) with prior positive Phase 3 data in China and MASH programs.
Key ratios
FCF / Sales
-1188.3%2023
ROA
-16.4%TTM
2025
-25.7%2024
-26.5%2023
-29.6%
ROE
-38.2%2025
2024
-36.9%2023
-47.0%
Revenue growth
-100.0%TTM
Recent news
Sagimet Biosciences Announces Participation in Upcoming Investor Conference and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Sagimet Biosciences Announces First Patient Dosed in AURORA Phase 3 U.S. Clinical Trial of Denifanstat for Moderate to Severe Acne
Sagimet To Present Positive Full 52-Week Results from License Partner Ascletis' Phase 3 Open-Label Extension Clinical Trial of Denifanstat in Acne and Mechanistic Data at the 2026 Fall Clinical Dermatology Conference
Sagimet Biosciences Announces Closing of Underwritten Offering of Series A Common Stock and Pre-Funded Warrants
Sagimet Biosciences Announces Pricing of $115.0 Million Underwritten Offering of Series A Common Stock and Pre-Funded Warrants
Sagimet Announces Positive Full 52-Week Results from License Partner Ascletis' Phase 3 Open-Label Extension Clinical Trial of Denifanstat in Acne Presented at EADV 2026
Sagimet Biosciences to Host Virtual KOL Event on Denifanstat Data September 30, 2026
Sagimet Biosciences Announces Participation in Two Upcoming Investor Conferences
Sagimet Biosciences Advances AURORA U.S. Phase 3 Trial of Denifanstat in Acne Toward Patient Enrollment in Q4 2026
Track SGMT in your journal
Save it to a watchlist, run a reverse DCF, and keep your notes on the company in one place. Free to start.
Figures are sourced from third parties and shown for research only. They may be delayed or incomplete, and nothing on this page is investment advice or a recommendation to buy or sell. Read the full disclaimer